c‐KIT‐ERK1/2 signaling activated ELK1 and upregulated carcinoembryonic antigen expression to promote colorectal cancer progression

Jian Ma,Xiaohui Liu,Hong Chen,Muhammad Khawar Abbas,Liu Yang,Haimei Sun,Tingyi Sun,Bo Wu,Shu Yang,Deshan Zhou
DOI: https://doi.org/10.1111/cas.14750
IF: 5.7
2020-12-19
Cancer Science
Abstract:<p>Carcinoembryonic antigen (CEA) is highly expressed in embryo and colorectal cancer (CRC) and has been widely used as a marker for CRC. Emerging evidences have proved that elevated CEA promotes CRC progression. However, the mechanism of the increased CEA in primary and recurrent CRC is still an open question. In this study, we showed that c‐KIT, ELK1 and CEA were hyper‐expressed in CRC patients especially recurrent ones. By bioinformatics we picked out ELK1 as a candidate transcription factor (TF) for CEA and the the binding site of ELK1 within CEA promoter was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays. Over‐expression of ELK1 increased CEA <i>in vitro</i>; while knock‐down of ELK1 decreased CEA. Up‐regulated ELK1 promoted adhesion, migration and invasion of CRC cells. However, knock‐down of CEA blocked the activities of the ELK1 over‐expressed CRC cells. Furthermore, we explored the role of the c‐KIT‐ERK1/2 signaling in the activation of ELK1. Blockage of the c‐KIT signaling by Imatinib or ISCK03 reduced p‐ELK1 and consequently decreased CEA in CRC cells; so did the blockage of the ERK1/2 pathway by U0126. Compared with wild type (WT) littermates, the <i>c‐kit</i> loss‐of‐functional Wads<sup>m/m</sup> mice showed lowered c‐KIT, ELK1 and CEA. In conclusion, our study revealed that ELK1, which was activated by the c‐KIT‐ERK1/2 signaling, was a key TF for CEA expression. Blockage of ELK1 or its up‐stream signaling could be an alternative way to decelerate CRC progression. We also suggested that besides a biomarker for CRC, CEA could be used for guiding targeted therapy.</p>
oncology
What problem does this paper attempt to address?